European Journal of Rheumatology
Literature Review

Antifibrotic therapies in rheumatoid arthritis associated interstitial lung disease

1.

Department of Internal Medicine and Rheumatology, University of Health Sciences, Basaksehir C am and Sakura City Hospital, _ Istanbul, Turkey

2.

Department of Chest Disease, Yedikule Chest Diseases and Chest Surgery Training and Research Hospital, Istanbul, Turkey

3.

Department of Rheumatology, University of Health Sciences, Bakırko¨ y Dr. Sadi Konuk, Training and Research Hospital, Istanbul, Turkey

Eur J Rheumatol 2022; 9: 176-179
DOI: 10.5152/eurjrheum.2021.21102
Read: 274 Downloads: 149 Published: 21 January 2022

bstract Interstitial lung disease (ILD) is one of the common extra-articular manifestations of rheumatoid arthritis (RA) and it is associated with high mortality rate. The usual interstitial pneumonia (UIP) pattern of RA associated ILD (RA-ILD) shows some similarities to idiopathic pulmonary fibrosis, suggesting that antifibrotic therapies may have potential positive affects. In this review, we discuss the effectiveness of antifibrotic therapy for RA-ILD.

Cite this article as: Bes C, Köybaşı G, İçaçan OC, Mutlu MY, Yıldırım F. Influence of anti-TNF-a treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study. Eur J Rheumatol. 2022;9(3):176-179.

Files
EISSN 2148-4279